Lilly Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LILLY, and what generic alternatives to LILLY drugs are available?
LILLY has one hundred and five approved drugs.
There is one US patent protecting LILLY drugs.
There are thirty patent family members on LILLY drugs in twenty-five countries and eighty-seven supplementary protection certificates in thirteen countries.
Drugs and US Patents for Lilly
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lilly | PAGITANE | cycrimine hydrochloride | TABLET;ORAL | 008951-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Lilly | DIETHYLSTILBESTROL | diethylstilbestrol | TABLET, DELAYED RELEASE;ORAL | 004039-005 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Lilly | HALDRONE | paramethasone acetate | TABLET;ORAL | 012772-005 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Lilly | NEOTRIZINE | trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine) | TABLET;ORAL | 006317-011 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Lilly | NEOMYCIN SULFATE | neomycin sulfate | TABLET;ORAL | 060385-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Lilly
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Lilly | SYMBYAX | fluoxetine hydrochloride; olanzapine | CAPSULE;ORAL | 021520-002 | Dec 24, 2003 | 5,229,382*PED | ⤷ Sign Up |
Lilly | CIALIS | tadalafil | TABLET;ORAL | 021368-003 | Nov 21, 2003 | 6,140,329 | ⤷ Sign Up |
Lilly | ALIMTA | pemetrexed disodium | POWDER;INTRAVENOUS | 021462-002 | Sep 7, 2007 | 7,772,209*PED | ⤷ Sign Up |
Lilly | FORTEO | teriparatide | SOLUTION;SUBCUTANEOUS | 021318-001 | Nov 26, 2002 | 7,550,434 | ⤷ Sign Up |
Lilly | DECABID | indecainide hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019693-003 | Dec 29, 1989 | 4,382,093 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LILLY drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2008-10-14 |
➤ Subscribe | Delayed-release Capsules | 20 mg, 30 mg and 60 mg | ➤ Subscribe | 2008-08-04 |
➤ Subscribe | Capsules | 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg | ➤ Subscribe | 2007-05-29 |
➤ Subscribe | Capsules | 3 mg/25 mg | ➤ Subscribe | 2008-05-08 |
➤ Subscribe | For Injection | 1g/vial | ➤ Subscribe | 2005-11-14 |
➤ Subscribe | For Injection | 100 mg/vial | ➤ Subscribe | 2008-07-01 |
➤ Subscribe | For Injection | 1000 mg/vial | ➤ Subscribe | 2012-06-27 |
➤ Subscribe | Injection | 250 mcg/mL, 2.4 mL prefilled Pen | ➤ Subscribe | 2015-07-27 |
➤ Subscribe | Tablets | 5 mg, 10 mg and 20 mg | ➤ Subscribe | 2007-11-21 |
➤ Subscribe | Delayed-release Capsules | 40 mg | ➤ Subscribe | 2012-05-10 |
➤ Subscribe | Capsules | 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg | ➤ Subscribe | 2005-01-10 |
➤ Subscribe | For Injection | 200 mg/vial | ➤ Subscribe | 2005-11-01 |
➤ Subscribe | For Injection | 2 g/vial | ➤ Subscribe | 2007-08-24 |
➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2008-02-04 |
➤ Subscribe | For Injection | 750 mg/vial | ➤ Subscribe | 2016-10-06 |
International Patents for Lilly Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Eurasian Patent Organization | 200601801 | ⤷ Sign Up |
European Patent Office | 1732628 | ⤷ Sign Up |
Japan | 2007530240 | ⤷ Sign Up |
Brazil | PI0509269 | ⤷ Sign Up |
Denmark | 1732628 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Lilly Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0720599 | CR 2014 00050 | Denmark | ⤷ Sign Up | PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910 |
2365988 | LUC00061 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM ET TOUS LES SELS ET DERIVES DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721 |
0740668 | PA2003001 | Lithuania | ⤷ Sign Up | PRODUCT NAME: TADALAFILUM ((6R,12AR)-2,3,6,7,12,12A-HEKSAHIDRO-2-METIL-6-(3,4-METILENDIOKSIFENIL)-PIRAZINO(2',1':6,1)PIRIDO(3,4-B)INDOL-1,4-DIONAS); REGISTRATION NO/DATE: 03/8034/3, 03/8035/3 20030328 |
1480644 | 2016/056 | Ireland | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF CEFTAZIDIME OR A SALT THEREOF, AND AVIBACTAM OR A SALT THEREOF; REGISTRATION NO/DATE: EU/1/16/1109/001 20160624 |
2365988 | 2018C/006 | Belgium | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM OF EERDER WELK ZOUT OF AFGELEIDE ERVAN; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.